261 related articles for article (PubMed ID: 18089438)
1. Is homocysteine toxic in uremia?
Perna AF; Luciano MG; Pulzella P; Satta E; Capasso R; Lombardi C; Ingrosso D; De Santo NG
J Ren Nutr; 2008 Jan; 18(1):12-7. PubMed ID: 18089438
[TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies.
Perna AF; Sepe I; Lanza D; Pollastro RM; De Santo NG; Ingrosso D
J Ren Nutr; 2012 Jan; 22(1):191-4. PubMed ID: 22200441
[TBL] [Abstract][Full Text] [Related]
3. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
[TBL] [Abstract][Full Text] [Related]
6. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of hyperhomocysteinemia and their management by folic acid.
Perna AF; De Santo NG; Ingrosso D
Miner Electrolyte Metab; 1997; 23(3-6):174-8. PubMed ID: 9387111
[TBL] [Abstract][Full Text] [Related]
8. Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit.
Perna AF; Ingrosso D; Violetti E; Luciano MG; Sepe I; Lanza D; Capasso R; Ascione E; Raiola I; Lombardi C; Stenvinkel P; Massy Z; De Santo NG
Semin Dial; 2009; 22(4):351-6. PubMed ID: 19708980
[TBL] [Abstract][Full Text] [Related]
9. [Homocysteine--risk factor or risk indicator?].
Rafflenbeul W
MMW Fortschr Med; 2005 Nov; 147(44):28-30. PubMed ID: 16302487
[TBL] [Abstract][Full Text] [Related]
10. It is important to lower homocysteine in dialysis patients.
Zoccali C; Mallamaci F; Tripepi G
Semin Dial; 2007; 20(6):530-3. PubMed ID: 17991199
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine in uremia.
Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemia in end-stage renal failure.
Kes P
Acta Med Croatica; 2000; 54(4-5):175-81. PubMed ID: 11379482
[TBL] [Abstract][Full Text] [Related]
14. "New" cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment.
Bayés B; Pastor MC; Bonal J; Romero R
Kidney Int Suppl; 2005 Jan; (93):S39-43. PubMed ID: 15613067
[TBL] [Abstract][Full Text] [Related]
15. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
Perna AF; Castaldo P; Ingrosso D; De Santo NG
J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine and oxidative stress.
Perna AF; Ingrosso D; De Santo NG
Amino Acids; 2003 Dec; 25(3-4):409-17. PubMed ID: 14661100
[TBL] [Abstract][Full Text] [Related]
18. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?
van Guldener C
Nephrol Dial Transplant; 2006 May; 21(5):1161-6. PubMed ID: 16490741
[No Abstract] [Full Text] [Related]
19. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications.
Perna AF; Ingrosso D; Castaldo P; De Santo NG; Galletti P; Zappia V
Miner Electrolyte Metab; 1999; 25(1-2):95-9. PubMed ID: 10207268
[TBL] [Abstract][Full Text] [Related]
20. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease.
Palleschi S; De Angelis S; Rossi B; Diana L; Papa V; Severini G; Splendiani G
Nephron Clin Pract; 2008; 108(2):c106-12. PubMed ID: 18212512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
